IBio, Inc Therapeutic and Drug Pipeline Review H2

Wise.Guy12

Wise.Guy.

IBio, Inc Therapeutic and Overview Pipeline Review H2

PUNE, INDIA, January 23, 2017 /EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by iBio, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Get Sample Report @ https://www.wiseguyreports.com/sample-request/649765-ibio-inc-product-pipeline-review-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope
- The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc.
- The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses iBio, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features iBio, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy
- Evaluate iBio, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for iBio, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding iBio, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
iBio, Inc. Snapshot 6
iBio, Inc. Overview 6
Key Information 6
Key Facts 6
iBio, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
iBio, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
iBio, Inc. - Pipeline Products Glance 13
iBio, Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
iBio, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
iBio, Inc. - Drug Profiles 16
anthrax vaccine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
HAI-05 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
influenza [strain A/H1N1] vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
malaria vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NaAPR1M-74 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
anthrax + plague vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
human papillomavirus [Serotype 16] vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
…Continued

Access Report @ https://www.wiseguyreports.com/reports/649765-ibio-inc-product-pipeline-review-2016

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here